| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -46.6 | -36.8 |
| EPS (diluted, $ a share) | $-0.81 | $-0.97 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: DNTH. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Dianthus Therapeutics, Inc.: key numbers
- Share price
- $86.98Close, Nov 17
- Market cap
- $4.9B
- Shares outstanding
- 56.31MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Dianthus Therapeutics, Inc.
All →Dianthus Therapeutics EVP, CFO & Cbo Ryan Savitz Sells $11.2M of Stock
Ryan Savitz, EVP, CFO & Cbo, sold 124,042 shares of Dianthus Therapeutics, Inc. at $85.16 to $91.59 a share (average $90.52) in 9 transactions, worth $11.2M in total between Nov 9, 2026 and Nov 12, 2026. Shares held after the trade: 0 (-100.0%).
- Value
- $11.2M
- Shares
- 124,042
- Average price
- $90.52
- Role
- EVP, CFO & Cbo
- Holding change
- -100.0%
- Trade date
- Nov 9, 2026 to Nov 12, 2026
Dianthus Therapeutics Financial Results
Dianthus Therapeutics reported Q3 2026 financial results and provided a clinical pipeline update, highlighting a cash position of approximately $1.2 billion. The company remains on track for Phase 2 MoMeNtum trial results in MMN in December 2026 and expects its current cash runway to fund operations into 2030.
“The Dianthus team continues to execute on our strategy to build a best-in-disease neuromuscular franchise with claseprubart across gMG, CIDP, and MMN, while advancing an exciting pipeline of potentially best-in-disease bifunctional fusion proteins with DNTH212 and DNTH312.”
Marino Garcia, Chief Executive Officer of Dianthus Therapeutics
Dianthus Therapeutics CAO Edward Carr Sells $2.03M of Stock
Edward Carr, CAO, sold 20,000 shares of Dianthus Therapeutics, Inc. at $100.43 to $104.39 a share (average $101.38) in 5 transactions, worth $2.03M in total on Sep 17, 2026. Shares held after the trade: 0 (-100.0%).
- Value
- $2.03M
- Shares
- 20,000
- Average price
- $101.38
- Role
- CAO
- Holding change
- -100.0%
- Trade date
- Sep 17, 2026